Evidence map›Paper›PMID 27835608›Full record

ArticleOncotarget2016

PC-1 works in conjunction with E3 ligase CHIP to regulate androgen receptor stability and activity.

Jian Wang, Hui Zhang, Xiaoqing Zhang, Peng Wang, Hongtao Wang, Fang Huang, Chenyan Zhou, Jianguang Zhou, Shanhu Li

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jian WangLaboratory of Medical Molecular Biology, Beijing Institute of Biotechnology, Beijing 100850, China.
Hui ZhangSchool of Medicine, Tsinghua University, Beijing 100084, China.
Xiaoqing ZhangLaboratory of Medical Molecular Biology, Beijing Institute of Biotechnology, Beijing 100850, China.
Peng WangLaboratory of Medical Molecular Biology, Beijing Institute of Biotechnology, Beijing 100850, China.
Hongtao WangLaboratory of Medical Molecular Biology, Beijing Institute of Biotechnology, Beijing 100850, China.
Fang HuangLaboratory of Medical Molecular Biology, Beijing Institute of Biotechnology, Beijing 100850, China.
Chenyan ZhouLaboratory of Medical Molecular Biology, Beijing Institute of Biotechnology, Beijing 100850, China.
Jianguang ZhouLaboratory of Medical Molecular Biology, Beijing Institute of Biotechnology, Beijing 100850, China.
Shanhu LiLaboratory of Medical Molecular Biology, Beijing Institute of Biotechnology, Beijing 100850, China.
Tsinghua University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The androgen receptor (AR) is not only a ligand-dependent transcription factor, but also functions as a licensing factor, a component of DNA replication, which is degraded during mitosis. Furthermore, the deregulation of AR activity is involved in the initiation of prostate cancer and contributes to castration resistant prostate cancer (CRPC). While AR degradation is known to occur primarily through a proteasome-mediated pathway, very little is known about how this process is regulated, especially in M phase. PC-1 is an androgen-responsive factor and expresses specificity in prostate cancer, with higher expression noted at G2/M. In this study, PC-1 was shown to interact with AR and E3 ligase CHIP (Carboxy-terminus of Hsc70 Interacting Protein) and to enhance AR/CHIP interactions, thereby decreasing AR stability. Moreover, PC-1 was found to act in conjunction with CHIP in the decreasing of AR via ubiquitination, with the subsequent degradation predominantly occurring during M phase. PC-1 was also found to repress AR transcriptional activity in androgen-dependent and androgen-independent prostate cancer cells and attenuate the growth inhibition of AR. In conclusion, these findings should provide new clues regarding the modulation of AR turnover and activity via PC-1 and reveals an essential role of PC-1 in AR signaling.

Indexed as

Cell Cycle CheckpointsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHEK293 CellsHumansMalePhosphoric Diester HydrolasesProstatic Neoplasms, Castration-ResistantProtein StabilityProteolysisPyrophosphatasesReceptors, AndrogenSignal TransductionTime FactorsTranscription, GeneticAR protein, humanectonucleotide pyrophosphatase phosphodiesterase 1Phosphoric Diester HydrolasesPyrophosphatasesReceptors, AndrogenSTUB1 protein, humanUbiquitin-Protein Ligasesandrogen receptorCHIPPC-1prostate cancerprotein degradation

Identifiers

PMID27835608
PMCPMC5348399
OpenAlexW2553168473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.